Obesity drugs face rollout and safety tests
Weight‑loss drugs are moving from early demand surges into real‑world rollout and regulatory scrutiny, with Eli Lilly told by the FDA to run post‑marketing studies on risks including liver and cardiovascular effects for its oral obesity pill. Lilly is already distributing the drug via cash‑pay channels and telehealth while Novo Nordisk is pairing with OpenAI on R&D tools and oral semaglutide has won FDA approval as the first GLP‑1 pill for weight loss (reuters.com, hlth.com, pharmaceutical-technology.com, ajmc.com).
Eli Lilly’s new obesity pill is moving into U.S. pharmacies just as federal regulators order extra safety studies after approval. (fda.gov) The pill, sold as Foundayo and known scientifically as orforglipron, won Food and Drug Administration approval on April 1, 2026 for adults with obesity or overweight plus at least one related condition. The agency cleared it after a 50-day review under its Commissioner’s National Priority Voucher program. (fda.gov) Eli Lilly began a nationwide launch on April 13 through LillyDirect, telehealth providers, pharmacies, digital health services and Amazon Pharmacy. HLTH reported self-pay prices starting around $149 a month for lower doses, while some commercially insured patients could pay as little as $25 with savings programs. (hlth.com) These medicines mimic glucagon-like peptide-1, a gut hormone that helps people feel full and slows stomach emptying. The shift from weekly shots to daily pills is opening a new lane in obesity treatment, not just a new brand launch. (ajmc.com) The market changed in December 2025, when the Food and Drug Administration approved Novo Nordisk’s oral semaglutide as the first glucagon-like peptide-1 pill for weight loss. Novo said it would launch the once-daily Wegovy pill in the United States in early January 2026. (ajmc.com) Lilly is trying to separate Foundayo from that pill on convenience. AJMC reported that Foundayo is the only glucagon-like peptide-1 pill for obesity that can be taken without food or water restrictions, while oral semaglutide’s format has been tied to stricter dosing routines. (ajmc.com) Clinical trial results gave Lilly a strong launch message. In Lilly’s phase 3 program, participants on the highest dose who stayed on treatment lost an average 27.3 pounds, or 12.4% of body weight, over 72 weeks, compared with 2.2 pounds on placebo. (ajmc.com) The business race is widening beyond prescriptions and pharmacies. Novo Nordisk said on April 14 that it will pilot OpenAI tools across research and development, manufacturing and commercial teams, with full integration expected by the end of 2026. (pharmaceutical-technology.com) That puts the obesity-drug fight on two tracks at once: real-world rollout and real-world scrutiny. Lilly now has to prove that broad access to a daily pill can scale while regulators keep testing how its risks look outside tightly controlled trials. (fda.gov)
